Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $966M | $990M | $902M | $1.44B | $1.77B | $1.00B | $863M | $713M | $607M |
| Revenue growth | — | -13.6% | 2.5% | -8.9% | 59.1% | 23.6% | -43.4% | -14.0% | -17.4% | -14.9% |
| Gross profit | — | — | — | — | — | — | $288M | $318M | $219M | $206M |
| Gross margin | — | — | — | — | — | — | 28.7% | 36.8% | 30.6% | 33.9% |
| Operating income | -$96.6M | -$276M | -$171M | -$274M | $57.7M | $18.8M | -$226M | -$157M | -$152M | -$117M |
| Operating margin | -8.6% | -28.6% | -17.3% | -30.4% | 4.0% | 1.1% | -22.5% | -18.2% | -21.3% | -19.3% |
| Net income | -$48.4M | -$305M | -$153M | -$315M | $30.6M | -$30.1M | -$328M | -$189M | -$53.2M | -$226M |
| Net margin | -4.3% | -31.6% | -15.5% | -34.9% | 2.1% | -1.7% | -32.7% | -21.9% | -7.5% | -37.2% |
| EPS (diluted) | -$0.10 | -$0.55 | -$0.27 | -$0.53 | $0.05 | -$0.05 | -$0.46 | -$0.25 | -$0.08 | -$0.30 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $32.0M | -$92.1M | -$109M | -$173M | $39.5M | $38.3M | -$95.2M | -$28.2M | -$183M | -$179M |
| Capital expenditures | $18.5M | $46.5M | $27.9M | $12.7M | $33.7M | $32.2M | $24.6M | $16.3M | $25.0M | $12.3M |
| Free cash flow | $13.5M | -$139M | -$137M | -$185M | $5.79M | $6.18M | -$120M | -$44.5M | -$208M | -$191M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $0.00 | $90.2M | $47.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $169M | $91.5M | $96.5M | $85.5M | $72.2M | $135M | $153M | $95.9M | $427M | $364M |
| Total assets | $2.77B | $2.59B | $2.45B | $2.31B | $2.47B | $2.40B | $2.17B | $2.01B | $2.20B | $1.93B |
| Total liabilities | $675M | $746M | $660M | $695M | $802M | $715M | $606M | $622M | $835M | $664M |
| Long-term debt | $717K | $1.57M | $4.65M | $3.91M | $251M | $205M | $9.29M | $7.73M | $3.00M | $2.26M |
| Shareholders' equity | $2.05B | $1.84B | $1.79B | $1.61B | $1.67B | $1.69B | $1.56B | $1.39B | $1.37B | $1.27B |
| Retained earnings | -$730M | -$1.05B | -$1.20B | -$1.51B | -$1.48B | -$1.51B | -$1.82B | -$2.01B | -$2.07B | -$2.29B |
| Shares (wtd avg diluted) | 556M | 559M | 563M | 595M | 641M | 648M | 719M | 752M | 694M | 751M |
Every figure is extracted from OPKO HEALTH, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.